secwatch.observer — SEC 8-K summary
======================================

Issuer:     GeoVax Labs, Inc. (GOVX)
CIK:        0000832489
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0001437749-25-034903
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GeoVax Q3 net loss $6.3M ($0.31/sh); BARDA contract terminated; Mpox vaccine accelerated
--------------------------------------------------------------------------------

- Net loss of $6.3M vs $5.8M in Q3 2024; per-share loss improved to $0.31 from $0.91 due to share count change.
- Revenue fell to $0 as BARDA terminated Project NextGen contract for convenience in April 2025, compared to $2.8M in Q3 2024.
- Cash $5.0M at Sep 30, 2025, down from $5.5M at Dec 31, 2024; burn rate continues.
- GEO-MVA accelerated amid global Mpox emergency; EMA supports streamlined regulatory pathway.
- GEO-CM04S1 met primary endpoint in CLL trial; Gedeptin expanding into new solid tumor indications.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/832489/000143774925034903/0001437749-25-034903-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/832489/000143774925034903/govx20251112_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-034903

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer